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Abstract
We report that daurinol, a novel arylnaphthalene lignan, is a promising potential anticancer agent with adverse effects
that are less severe than those of etoposide, a clinical anticancer agent. Despite its potent antitumor activity, clinical
use of etoposide is limited because of its adverse effects, including myelosuppression and the development of sec-
ondary leukemia. Here, we comprehensively compared the mechanistic differences between daurinol and etoposide
because they have similar chemical structures. Etoposide, a topoisomerase II poison, is known to attenuate cancer
cell proliferation through the inhibition of DNA synthesis. Etoposide treatment induces G2/M arrest, severe DNA dam-
age, and the formation of giant nuclei in HCT116 cells. We hypothesized that the induction of DNA damage and nu-
clear enlargement due to abnormal chromosomal conditions could give rise to genomic instability in both tumor cells
and in actively dividing normal cells, resulting in the toxic adverse effects of etoposide. We found that daurinol is a
catalytic inhibitor of human topoisomerase IIα, and it induces S-phase arrest through the enhanced expression of
cyclins E and A and by activation of the ATM/Chk/Cdc25A pathway in HCT116 cells. However, daurinol treatment
did not cause DNA damage or nuclear enlargement in vitro. Finally, we confirmed the in vivo antitumor effects and
adverse effects of daurinol and etoposide in nudemice xenograft models. Daurinol displayed potent antitumor effects
without any significant loss of bodyweight or changes in hematological parameters, whereas etoposide treatment led
to decreased body weight and white blood cell, red blood cell, and hemoglobin concentration.
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Introduction
Myelosuppression, a decrease in blood cell production due to bone
marrow cell abnormalities, is one of the most common and serious ad-
verse effects of cancer chemotherapy [1]. Clinically, myelosuppression
is characterized by hematological changes, such as a decrease in the
number of red blood cells (anemia), white blood cells (leukopenia or
neutropenia), and platelets (thrombocytopenia) [1,2]. Etoposide (VP-16),
an aryltetraline lignan, is a clinical antitumor drug used to treat various
human cancers, including small cell lung cancer and testicular cancer
[3,4]. However, the adverse effects of etoposide reported in clinical
trials include both myelosuppression and the development of secondary
cancers, particularly etoposide-induced leukemia [2,3,5]. Etoposide-
induced myelosuppression during cancer chemotherapy has also been
reported in animal models [6], and combinatorial treatment with other
chemical compounds, such as dexrazoxane, quercetin, and wongonin, has
been performed to ameliorate etoposide-induced damage to bone marrow
cells in animal studies [7–10].
Etoposide inhibits the activity of human topoisomerase IIα. It is
classified as a topoisomerase II poison because it stabilizes the DNA-
topoisomerase complex (also called the DNA cleavable complex) [11].
In contrast, a compound that interferes with at least one step of the
catalytic cycle of topoisomerase II without the formation of the
DNA cleavable complex is classified as a catalytic topoisomerase inhib-
itor [12]. By forming the DNA cleavable complex, etoposide induces
severe genotoxic DNA damage in cancer cells and normal bone marrow
cells [10,13]. Consequently, this genotoxic DNA damage increases
aberrant DNA recombination events and accelerates abnormal chromo-
some rearrangements that seem to be connected to the adverse effects of
etoposide [6,14]. Etoposide induces G2/M phase arrest [15–17] as well
as the formation of abnormally shaped giant cell and nuclei in various
cancer cells, likely because cells cannot enter mitosis despite sufficient
synthesis of DNA and proteins for cell division [18,19]. Thus, we
hypothesized that the formation of giant nuclei and abnormal chromo-
somal rearrangements induced by etoposide treatment could be the
main reasons for its toxic side effects. Therefore, chemicals with sim-
ilar properties that do not induce DNA damage and nuclear enlarge-
ment may act as good clinical substitutes for etoposide, with fewer
adverse effects.
Daurinol is a novel natural arylnaphthalene lignan whose structure
is quite similar to etoposide. Daurinol is isolated from a traditional
ethnopharmacological plant, Haplophyllum dauricum, which has his-
torically been used to treat tumors in Russia [20,21]. The first report
of daurinol isolation was published in 1981 [20], but its biological
and pharmacological activity has never been investigated yet. Antipro-
liferative activities of arylnaphthalene lignans against various human
cancer cells have been reported, but the molecular mechanism of their
antiproliferative effects is still poorly elucidated [22–24].
Here, we propose that daurinol may be a novel alternative to the
clinical anticancer agent etoposide. To support this, we compared the
effects of daurinol and etoposide in vitro and in vivo. In addition, we
characterized the detailed molecular mechanism of the anticancer
activity of daurinol. This approach provides practical information
for the development of anticancer agents with lower adverse effects,
such as myelosuppression, and elucidates the molecular mechanism
underlying the inhibition of cancer cell proliferation induced by this
naturally occurring arylnaphthalene lignan.
Materials and Methods
Materials
Daurinol was isolated from the Mongolian medicinal plant H.
dauricum as previously described [20]. Etoposide, propidium iodide,
Cremophor, ethanol, and calf thymus DNA were purchased from Sigma
(St Louis, MO). The chemical structures of daurinol and etoposide are
shown in Figure 1A. Daurinol and etoposide were dissolved in dimethyl
sulfoxide (DMSO) for cellular treatment in vitro. Human topoisome-
rase IIα was purchased from TopoGEN (Port Orange, FL). Antibodies
against p-ATM (Ser1981) (4526), ATM (2873), p-Chk1 (Ser317)
(2344), p-Chk1 (Ser345) (2341), Chk1 (2345), p-Chk2 (Thr68)
(2661), Chk2 (2662), Cdc25A (3652), p-Cdc2 (Tyr15) (4539),
Cdc2 (9112), E2F-1 (3742), cyclin A (4656), Cdk4 (2906), and cyclin
D1 (2922) were purchased from Cell Signaling Technology (Danvers,
MA). Antibodies against Cdk2 (sc-163), cyclin E (sc-247), and β-actin
(sc-47778) were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA). The antibody against p-Cdk2 (Tyr15) (ab76146) was pur-
chased from Abcam (Cambridge, United Kingdom). Secondary anti-rabbit
and anti-mouse antibodies were purchased from Santa Cruz Biotechnology.
Cell Culture
SW480, DLD-1, and HCT116 human colorectal cancer; A549
human lung cancer; AGS human gastric cancer; HepG2 human liver
cancer; and MCF-7 human breast cancer cell lines were obtained
from the American Type Culture Collection (Rockville, MD).
HCT116, DLD-1, and MCF-7 cells were cultured in minimal essen-
tial medium (MEM) supplemented with 10% fetal bovine serum
(FBS), 100 U/ml penicillin, and 100 μg/ml streptomycin. A549,
AGS, and SW480 cells were maintained in Roswell Park Memorial
Institute 1640 medium supplemented with 25 mM HEPES, 10%
FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin. HepG2 cells
were cultured in Dulbecco modified Eagle medium supplemented
with 10% FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin.
Cells were cultured in a humidified atmosphere (95% air, 5% CO2)
at 37°C.
Figure 1. Daurinol inhibits cell proliferation and DNA synthesis. (A) Chemical structures of daurinol and etoposide. (B) Antiproliferative
activity of daurinol was determined by cell viability assays in various human cancer cell lines. Cells were treated with various concentra-
tions of daurinol for 24 and 48 hours. IC50, the concentration that inhibits 50% of cell proliferation. Means ± SD from three independent
experiments are shown. (C) Inhibition of cell viability and DNA synthesis by treatment with daurinol or etoposide for 24 and 48 hours was
determined by CCK-8 assay (mitochondrial dehydrogenase activity) and BrdU incorporation ELISA in HCT116 cells. Cell viability (%) and
BrdU incorporation (%) were calculated as percents of the vehicle control. Data are expressed as mean ± SD from triplicate experiments.
**P < .01 and ***P < .001, for significant differences from the vehicle control. Graphs are representative of three independent experi-
ments. (D) Cell viability versus BrdU incorporation (left). Relative DNA synthesis was calculated by BrdU incorporation (%) over cell viability
(%) (right). Columns and error bars indicate mean ± SD. *P< .05, **P< .01, and ***P< .001, for significant differences from the vehicle
control. Graphs are representative of three independent experiments.
1044 Antitumor Effect of Daurinol with Low Side Effects Kang et al. Neoplasia Vol. 13, No. 11, 2011
Measurement of Cell Viability and DNA Synthesis
Tomeasure the antiproliferative activity of daurinol in various cancer
cell lines, cell viability was determined by measurement of mitochon-
drial dehydrogenase activity using a Cell Counting Kit (CCK-8) pur-
chased from Dojindo Laboratories (Tokyo, Japan), as previously
described [25]. Briefly, cancer cells (5 × 103 cells per well) were plated
in 96-well plates, incubated at 37°C for 24 hours, and treated with 0 to
100 μM daurinol for 24 and 48 hours.
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We also measured the cell viability and DNA synthesis of HCT116
andDLD-1 cells treated with daurinol or etoposide using CCK-8 assays
and 5-bromo-2′-deoxyuridine (BrdU) incorporation enzyme-linked
immunosorbent assay (ELISA), respectively. BrdU incorporation was
measured using a Cell Proliferation ELISA BrdU Kit (Roche, Mannheim,
Germany) according to the manufacturer’s instructions. Briefly, HCT116
and DLD-1 cells (5 × 103 cells per well) were plated in 96-well plates,
incubated at 37°C for 24 hours, and treated with 1.25 to 20 μMdaurinol
or etoposide for 24 and 48 hours. The BrdU labeling solution was added
during the last 2 hours of the treatment. Cell survival (%) and BrdU
incorporation (%) were calculated as the percentage of the absorbance
at 450 nm of chemical-treated cells compared to control cells treated
with only DMSO.
BrdU incorporation measured by ELISA may decrease owing to
the inhibition of DNA synthesis or decreased cell viability. To solve this
problem, we measured both the BrdU incorporation and cell viability
of our cell lines at different stages of confluence. We plated different
numbers of HCT116 and DLD-1 cells (6.25 × 102, 1.25 × 103, 2.5 ×
103, 5 × 103, and 1 × 104 cells per well) in 96-well plates, incubated at
37°C for 24 hours, and treated with 5 μMdaurinol or 10 μM etoposide
for 24 and 48 hours. The CCK-8 cell viability assay and BrdU labeling
solutions were added during the last 2 hours of the treatment. Then,
cell viability and BrdU incorporation were determined using spectro-
photometry. We calculated the relative DNA synthesis as the percent-
age of BrdU incorporation (%) over cell viability (%).
Cell Cycle Analysis
Cell cycle profiles were obtained by DNA content analysis using
a flow cytometer (Becton Dickinson, San Jose, CA) and Modfit LT
3.0 software, as previously described [25]. Briefly, HCT116 and
DLD-1 cells (5 × 105 cells) were seeded in 60-mm dishes, incubated
for 24 hours, and treated with 0 to 10 μMdaurinol for 24 to 72 hours.
We also confirmed the effect of daurinol on cell cycle progression in
HCT116 cells in both G0/G1 and G1/S synchronized conditions. For
G0/G1 phase synchronization, HCT116 and DLD-1 cells (2 × 10
5)
were seeded on 60-mm dishes, incubated at 37°C for 24 hours, and
pretreated with serum-free MEM for 24 hours. Then, 0 to 10 μM
daurinol was added for 24 and 48 hours in normal MEM containing
10% FBS. For G1/S–phase synchronization, HCT116 and DLD-1
cells (2 × 105) were seeded on 60-mm dishes, incubated at 37°C
for 24 hours, and pretreated with 2 mM hydroxyurea for 12 hours.
Cells were washed twice with Dulbecco phosphate-buffered saline
(DPBS) and once with medium to remove the residual hydroxyurea.
Then, 0 to 10 μM daurinol was added for 12, 24, and 48 hours. Both
floating and adherent cells were harvested by trypsinization and
fixed in 70% ethanol at −20°C for at least 1 day. Cells were stained
with propidium iodide, and their DNA contents were analyzed by
flow cytometry.
Topoisomerase IIα Inhibition Assay
The inhibitory activity of daurinol and etoposide against human
topoisomerase IIα was measured by in vitro biochemical assay using a
Topoisomerase II Drug Screening Kit (TopoGEN). The standard
reaction mixture (20 μl) contained 50 mM Tris-HCl (pH 8.0),
150 mM NaCl, 10 mM MgCl2, 0.5 mM dithiothreitol, 30 μg of
bovine serum albumin, 2 mM ATP, 375 ng of supercoiled DNA
(pHOT1), 2 μl of topoisomerase IIα, and 2 μl of tested compound
dissolved in DMSO. The reaction mixture was incubated at 37°C for
30 minutes, and 2 μl of 10% sodium dodecyl sulfate was added to
stop the reaction. Then, proteinase K (50 μg/ml final concentration) was
added, and the reactions were incubated for an additional 15 minutes
to remove topoisomerase IIα from the DNA. The reaction mixtures
were cleaned by extraction with a 25:24:1 phenol-chloroform-isoamyl
alcohol solution. DNA relaxation was evaluated by agarose gel electro-
phoresis both in the presence and in the absence of ethidium bromide.
The DNA samples were electrophoresed through 1% agarose gels at
1.7 V/cm for 30 minutes in 40 mM Tris-acetate and 1 mM EDTA
buffer and imaged with an i-MAX Gel Image Analysis System (Core Bio
System, Seoul, Republic of Korea).
Comet Assay
DNA damage was evaluated using single-cell gel electrophoresis
with a Trevigen kit (Gaithersburg, MD), as previously described [26].
Briefly, HCT116 cells (3 × 105 cells per well) were plated in six-well
plates, incubated for 24 hours, and treated with 0 to 50 μMdaurinol or
10 μM etoposide for 6 hours. Cells were harvested by trypsinization
and resuspended in ice-cold DPBS. Then, cells (2 × 103) were mixed
with 100 μl of low-melting agarose at 37°C, spread on slides precoated
with normal agarose, and solidified in the dark for 30 minutes at 4°C.
Slides were lysed in ice-cold lysis solution in the dark for 50 minutes at
4°C and then incubated in an alkaline solution (pH > 13) at room tem-
perature for 40 minutes to allow alkaline unwinding. Electrophoresis
was performed under alkaline conditions for 50 minutes at 1 V/cm
in a cold room (4°C). Slides were washed twice with distilled water,
once with 70% ethanol, and stained with 2.5 μg/ml propidium iodide
in distilled water for 20 minutes. Comet images were obtained using a
fluorescence microscope (TE2000U; Nikon, Kanawa, Japan), and per-
cent DNA in tail was calculated using TriTek CometScore 1.5 software
(Sumerduck, VA).
Measurement of Interaction between Daurinol and DNA
Interaction between daurinol and DNA was evaluated by fluores-
cence quenching experiment. The absorption spectrum of daurinol
dissolved in DPBS with 1% DMSO was obtained using a UV-visible
spectrophotometer (Lamda35; PerkinElmer, Waltham, MA). Fluores-
cence spectra were recorded on a microplate reader (Infinite M1000;
Tecan, Männedorf, Switzerland) at room temperature in the range of
400 to 650 nm with an excitation wavelength of 260 nm. The concen-
tration of calf thymus DNA was determined according to the absor-
bance at 260 nm using the molar absorption coefficient (ɛDNA)
6600/M/cm. To measure the fluorescence emission spectrum, daurinol
was dissolved in DPBS with 1% DMSO. For the fluorescence quench-
ing experiment, 30 μM daurinol and different concentrations of calf
thymus DNA (0-3.9 mM) were dissolved in DPBS with 1% DMSO.
The Stern-Volmer quenching constant (K SV) was calculated according
to the Stern-Volmer equation:
F0 = F = 1 + KSV ½DNA
where F0 and F are the fluorescence intensity in the absence and pres-
ence of DNA (quencher), respectively.
Measurement of Nuclear Size
Cellular morphologic changes after treatment with daurinol or
etoposide were observed by differential interference contrast microscopy
using a fluorescence microscope (TE2000U; Nikon). Changes of nuclei
sizes were evaluated by fluorescent microscopy and flow cytometric
fluorescence pulse width analysis (FL2-W) after cells were stained with
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propidium iodide, according to previously described methods [18].
HCT116 cells (5 × 105 cells) were seeded on 60-mm dishes, incubated
for 24 hours, and then treated with 0 to 10 μM daurinol or 10 μM
etoposide for 24 and 48 hours.
Western Blot Analysis
HCT116 cells (5 × 105) were seeded on 60-mm dishes, incubated
for 24 hours, and then treated with 5 μM daurinol for 2, 12, 24, and
48 hours. Additional procedures were performed as previously described
[27]. Relative protein expression was measured by densitometry.
Mouse Tumor Xenografts and Treatments
Five-week-old athymic male nude mice (BALB/c Slc-nu) were pur-
chased from SLC, Inc (Shizuoka, Japan). The mice were maintained
in ventilated caging with a 12-hour light/12-hour dark photoperiod.
Sterile food pellets (Teklad-certified irradiated global 18% protein rodent
diet 2918C; Harlan Teklad) and water were provided ad libitum.
Tumor xenografts were established by subcutaneous injection of 1 ×
107 HCT116 cells and maintained by serial transplantation. Tumor
fragments (3 × 3 × 3 mm3) were subcutaneously transplanted to the
left lateral flank of athymic mice. Tumor volumes were measured using
calipers and the formula V = 0.5 × length × width2. When the tumor
volume reached approximately 110 mm3, mice were randomized into
treatment groups of 10 animals per group. Two independent experi-
ments were performed. The first experiment was performed to evaluate
toxicity, antitumor activity, and their persistence of daurinol and etopo-
side. Mice were treated by intraperitoneal injection of solvent (4.2%
DMSO, 10.4% Cremophor, 10.4% ethanol, and 75% PBS), daurinol
(1, 5, 10, and 20 mg/kg), or etoposide (20 mg/kg) three times weekly
for 2 weeks. Mice were then maintained for additional 2 weeks. Body
weight and tumor volume were measured twice a week. On day 29,
mice were killed, and tumors were removed and photographed. The
second round of experiments was performed to confirm antitumor
activity and to investigate changes in hematological parameters, protein
expression, and histology. Mice were treated by intraperitoneal injec-
tion of solvent (4.2% DMSO, 10.4% Cremophor, 10.4% ethanol, and
75% PBS), daurinol (5, 10, and 20 mg/kg), or etoposide (20 mg/kg)
twice weekly for 3 weeks. Body weight was measured twice a week, and
tumor volume was measured three times a week. On day 18, mice were
killed, and tumors were removed for BrdU immunohistochemistry and
Western blot analysis. BrdU labeling was performed by the intraperito-
neal injection of 0.2 ml of BrdU solution (5 mg/ml; Sigma) 2 hours
before harvesting tumors. Kidney, colon, liver, and femur were also re-
moved and fixed in 10% neutral-buffered formalin (BBC Biochemical,
Mount Vernon, WA) for histologic analysis.
Histology and BrdU Immunohistochemistry
The fixed tumor, bone marrow, colon, kidney, and liver tissues
were decalcified (femur), embedded in paraffin, and used for hema-
toxylin and eosin staining. For BrdU immunohistochemistry, the
unstained tumor slides were incubated in 0.3% H2O2 for 30 minutes
to block endogenous peroxidase activity. Antigen retrieval was per-
formed by heating slides in 10 mM citrate buffer (pH 6.0) for 6 minutes
and washing three times with PBS. Then, slides were incubated in the
blocking agent (Immunotech, Marseille, France) for 1 hour and incu-
bated with mouse anti-BrdU antibody (Dako, Glostrup, Denmark) in
antibody dilution buffer (Immunotech) for 1 hour at room tempera-
ture. Slides were incubated with secondary antibody conjugated with
peroxidase (Immunotech) for 10 minutes. Then, the color-producing
reaction was performed using 3,3′-diaminobenzidine (DAB; Dako) for
15 minutes. The slides were counterstained with hematoxylin, and
stained slides were visualized by light microscopy. Hematoxylin- and
BrdU-positive cells were counted in three marginal areas of tumors
for each individual (n = 10), and the percentage of BrdU-positive cells
was calculated.
Hematological Parameter Analysis
Blood samples were collected from the abdominal vein and stored in
EDTA-coated tubes (Becton Dickinson, Franklin Lakes, NJ). Hema-
tological parameters were immediately determined using an Avida120
hematology analyzer (Siemens, Munich, Germany).
Statistical Analyses
Statistical analyses were performed by one-way analysis of variance
followed by the Dunnett multiple comparison test or the Tukey mul-
tiple comparison test using GraphPad Prism 5 software (GraphPad
Software, Inc, La Jolla, CA). P < .05 was considered statistically signif-
icant. Kolmogorov-Smirnov statistics were used to compare the distri-
butions of two histogram plots obtained by flow cytometry [28].
Results
Daurinol Inhibits Cancer Cell Proliferation
First, we tested the ability of daurinol to inhibit cell proliferation
in various human cancer cells by measurement of mitochondrial de-
hydrogenase activity. Daurinol displayed a potent antiproliferative
effect on various human cancer cells with IC50 values (concentration
that inhibits 50% of cell proliferation) below 20 μM after 48 hours
of treatment (Figure 1B). Daurinol demonstrated the greatest anti-
proliferative activity in human colorectal cancer HCT116 cells, with
IC50 values of 23.19 ± 0.67 at 24 hours and 2.03 ± 0.18 μM at
48 hours of treatment (Figure 1B). Therefore, we chose HCT116 cells
as a model cell line in which to investigate the molecular mechanism of
the antiproliferative effect of daurinol.
Daurinol Inhibits DNA Synthesis in HCT116 Cells
We hypothesized that the antiproliferative activity of daurinol was
due to the inhibition of DNA synthesis. To test this, we measured
cell viability and DNA synthesis after treatment with daurinol using
CCK-8 and BrdU incorporation assays. Daurinol significantly inhib-
ited cell viability (mitochondrial dehydrogenase activity) and BrdU
incorporation (DNA synthesis) in HCT116 cells at all concentrations
tested (1.25-20 μM). Etoposide was a more potent inhibitor of DNA
synthesis (BrdU incorporation) than cell viability (mitochondrial dehy-
drogenase activity; Figure 1C ). To confirm whether the decrease in
BrdU incorporation by daurinol was due to blocking DNA synthesis
rather than decreased cell viability by other cytotoxic effects, we per-
formed an additional experiment in which we measured cell viability
and BrdU incorporation at the same time in HCT116 cells at different
levels of confluence after treatment with 5 μM daurinol or 10 μM
etoposide and plotted cell viability versus BrdU incorporation. We then
estimated the inhibition of DNA synthesis based on the distribution of
the data. Both daurinol and etoposide displayed reduced BrdU incor-
poration rather than reduced cell viability compared to the vehicle con-
trol. The relative DNA synthesis indices (the percentage of BrdU
incorporation by cell viability) of daurinol and etoposide were signifi-
cantly lower than that of the vehicle control at both 24 and 48 hours
of treatment (Figure 1D). We also measured cell viability and BrdU
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incorporation in another colon cancer cell line, DLD-1, and found
similar inhibitory activity (Figure W1). Taken together, we concluded
that daurinol is a potent natural inhibitor of DNA synthesis.
Daurinol Induces S-phase Arrest in HCT116 Cells
Next, we investigated the effect of daurinol on the cell cycle progres-
sion of HCT116 cells using flow cytometric DNA content analysis.
Daurinol (5 μM) induced S-phase arrest at 24, 48, and 72 hours of
treatment (Figure 2A) in a dose-dependent manner (Figure 2B). We
confirmed daurinol-induced S-phase arrest under G1/S synchronized
conditions via hydroxyurea synchronization (Figure 2C ) and under
G0/G1 synchronization conditions via serum starvation (data not
shown), as described in Materials and Methods. We also observed that
daurinol induced S-phase arrest in DLD-1 cells (Figure W2). Because
DNA replication occurs during the S-phase, we assumed that daurinol-
induced S-phase arrest was due to the abrogation of DNA replication
by the inhibitory activity of daurinol. Etoposide is known to be a potent
Figure 2. Daurinol induces S-phase arrest in HCT116 cells. Cell cycle distribution was evaluated by using flow cytometric DNA content
analysis. (A) HCT116 cells were treated with 5 μM daurinol for 24, 48, and 72 hours. Columns and error bars indicate mean ± SD from
triplicate experiments. *P< .05 and ***P< .001, for significant differences from the vehicle control at each treatment time. The graph is
representative of three independent experiments. (B) HCT116 cells were treated with various concentrations of daurinol (0, 2.5, 5, and
10 μM) for 48 hours. Columns and error bars indicate mean ± SD from quadruplicate experiments. ***P< .001, for significant differences
from the vehicle control. (C) Daurinol-induced S-phase arrest of HCT116 cells was confirmed in hydroxyurea-synchronized cells. Cells
were pretreated with 2 mM hydroxyurea (HU) for 12 hours to synchronize in the G1/S–phase. Then, cells were treated with daurinol
(0, 2.5, 5, and 10 μM) for 12, 24, and 48 hours. C indicates vehicle control. The graph is representative of three independent experiments.
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agent for the induction of G2/M–phase arrest in various cancer cells
[4,12,18,29]. This difference in phases of cell cycle blockage was the
first noticeable distinction between daurinol and etoposide, although
both are inhibitors of DNA synthesis.
Daurinol Is a Catalytic Inhibitor of Human
Topoisomerase IIα
We next examined the inhibitory activity of daurinol against human
topoisomerase IIα using an in vitro biochemical assay that measures the
relaxation of supercoiled DNA. Etoposide is a well-known topoisom-
erase poison, and it stabilizes the DNA cleavable complex [13]. Both
etoposide and daurinol inhibited human topoisomerase IIα, preventing
unwinding of the supercoiled DNA substrate (Figures 3A and W3). As
previously reported [13], etoposide induced the formation of open cir-
cular and linear DNA, which originated from the topoisomerase-DNA
cleavable intermediate, but daurinol did not give rise to any open cir-
cular or linear DNA (Figure 3A).
We also measured DNA damage after treatment with daurinol or
etoposide in HCT116 cells using comet assays. Etoposide (10 μM)
clearly induced the formation of comet tails, indicating that etoposide
significantly induces DNA damage (% DNA in tail). In contrast, even
50 μM daurinol did not induce the formation of DNA comet tails
(Figure 3, B and C). Because the formation of comet tails implies severe
DNA damage in cells, we concluded that DNA damage induced by
etoposide treatment is much greater than that of daurinol. The forma-
tion of comet tail occurs when the DNA cleavable complex is formed
in cells, which is an important property of topoisomerase poisons [30].
Therefore, we concluded that daurinol must be a catalytic inhibitor of
human topoisomerase IIα rather than a topoisomerase poison because
treatment with daurinol induces less DNA damage compared to the
etoposide treatment. This was the second key distinction between
daurinol and etoposide.
We also measured the biophysical interaction between daurinol
and DNA using fluorescence quenching experiments to test whether
Figure 3. Daurinol is a catalytic inhibitor of human topoisomerase IIα. (A) Inhibitory activity of daurinol and etoposide on human topo-
isomerase IIα was evaluated by in vitro biochemical assays. The supercoiled DNA (pHOT1) substrate was incubated with human topo-
isomerase IIα in the presence of daurinol (1 and 2 mM) or etoposide (0.5 and 2 mM). DNA relaxation was evaluated by 1% agarose gel
electrophoresis in the presence of ethidium bromide. (B and C) Effects of daurinol and etoposide on DNA damage were determined by
comet assays. HCT116 cells were treated with daurinol (5, 20, and 50 μM) or 10 μM etoposide for 6 hours. (B) Images of cellular DNA
damage were detected by fluorescence microscopy. Pictures are representative of three independent experiments. (C) The DNA damage
index (% DNA in tail) was determined using comet score software. Columns and error bars indicate mean ± SD (n= 50). ***P< .001, for
significant differences from the vehicle control.
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catalytic inhibition of topoisomerase by daurinol involves an actual
interaction between daurinol and DNA. Through UV-visible spec-
troscopy, we determined that daurinol has an absorbance maximum
at 259.4 nm (Figure W4). Daurinol emitted fluorescence at 480 nm
with an excitation wavelength of 260 nm. The fluorescence intensity
of daurinol displayed a linear relationship with its concentration
(Figure W5B), confirming that the fluorescence was emitted from
daurinol. On addition of calf thymus DNA, the fluorescence of
daurinol was efficiently quenched (Figure W5C ). Theoretically,
quenching of daurinol fluorescence is due to the physical interaction
between daurinol and DNA (Figure W5A). We calculated the Stern-
Volmer quenching constant (K SV), which indicates the interaction
strength between biomolecules, using the Stern-Volmer equation
and found that the K SV was 635.7 ± 60.2 M
−1 (Figure W5D). This
interaction intensity was comparable to that of quinolone antibiotics,
R-ofloxacin (746 M−1) and synthetic alkaloids, luotonin A derivatives
(571-945 M−1) [31,32]. We speculated that the interaction of daurinol
and DNA may at least partially contribute to the inhibition of topo-
isomerase and DNA synthesis.
Daurinol Induces S-phase Arrest through Enhanced
Expression of Cyclins E and A and Activation of the
ATM/Chk/Cdc25A Pathway
To elucidate the molecular mechanism underlying the cell cycle
block induced by daurinol, we examined the phosphorylation state
and expression of cell cycle regulatory proteins in HCT116 cells
treated with daurinol. First, we investigated cyclin E and cyclin A
expression because Cdk2/cyclin E and Cdk2/cyclin A complexes are
involved in the initiation and progression of the S-phase, respectively
[33–35]. The expression of cyclin E rapidly increased at early times
(12 and 24 hours) of the daurinol treatment compared with the ve-
hicle control (Figure 4, A and I ). The expression of cyclin A was sig-
nificantly increased at 24 and 48 hours after daurinol treatment
(Figure 4, A and J ). In addition, the expression of E2F-1 was signif-
icantly increased at 24 hours after treatment (Figure 4, A and H ). We
also investigated the ATM/Chk/Cdc25A pathway, which is an im-
portant signaling pathway that regulates the DNA replication and
DNA damage checkpoint. Treatment with daurinol activated this
pathway at late time points (24 and 48 hours), as the phosphorylation
levels of ATM at Ser1981, Chk1 at Ser317 and Ser345, and Chk2
at Thr68 were significantly increased (Figure 4, A–E). Expression of
Cdc25A was also significantly decreased at 48 hours (Figure 4, A
and K ). Cdc25A is a downstream signaling component of Chk1/2
[33,36,37] and a signaling phosphatase that activates Cdk2 and
Cdc2 by dephosphorylating their Tyr15 residues, which is impor-
tant for cyclin-dependent kinase regulation of G1/S (Cdk2) and
G2/M transitions (Cdc2) [36,38]. We also observed an increase in
the phosphorylation of Cdk2 at Tyr 15 and Cdc2 at Tyr15 (Figure 4,
A and F and G ), suggesting that daurinol inhibits the G1/S and
G2/M checkpoints.
In Contrast to Etoposide, Daurinol Does Not Induce a Nuclear
Enlargement in HCT116 Cells
Etoposide induces the formation of giant cells and nuclei in cancer
cells, including HCT116 cells [18,32]. Observations using differen-
tial interference contrast microscopy revealed that 48 hours of daurinol
treatment does not induce changes in cell and nuclear enlargement, as
seen after etoposide treatment (Figure W6). We also measured nuclear
size after treatment with daurinol using fluorescent microscopy and
fluorescence pulse width analysis. Fluorescence microscopic observa-
tion and quantification of nuclear size using the circle measurement
algorithm of the microscope software revealed that daurinol does not
trigger nuclear enlargement compared to the vehicle control. Nuclear
sizes in daurinol-treated cells were similar to vehicle control cells,
whereas those of etoposide-treated cells were significantly larger
(Figure 5, A–C ). Flow cytometric pulse width analysis also demon-
strated that daurinol treatment does not induce a significant enlarge-
ment of cells or nuclei, as opposed to etoposide treatment. The FSC-H
and FL2-W values (which refer cell size and nuclear size, respectively) of
the daurinol-treated cells had a similar distribution to vehicle-treated
control cells, whereas etoposide-treated cells occupied much higher
positions than controls (Figure 5D). The mean values of FSC-H (which
refers to cell size) were 418.8 ± 22.0 for the vehicle control, 411.8 ±
9.4 for 5 μM daurinol-treated cells, and 544.0 ± 11.8 for 10 μM
etoposide-treated cells at 48 hours. The mean values of FL2-W (which
refers to nuclear size) were 207.1 ± 0.5 for the vehicle control, 203.2 ±
0.8 for 5 μM daurinol, and 322.6 ± 3.1 for 10 μM etoposide treat-
ments. We also compared distributions on histogram plots using
Kolmogorov-Smirnov statistics, which estimate the differential distri-
bution of two histogram plots. The D/s(n) (the index of similarity)
values of the daurinol-treated cells (2.5, 5, 10 μM for 48 hours) com-
pared to vehicle control cells were significantly lower than those of
etoposide-treated cells (10 μM for 48 hours; Figure 5E ). Changes in
nuclear size after treatment with daurinol and etoposide were also mea-
sured at 24 hours after treatment and were similar to the results of the
48-hour treatment (Figure W7).
This was the third crucial distinction between daurinol and etopo-
side. This difference between the effects of daurinol and etoposide
may be the most important for chemotherapeutic applications. We
hypothesized that the adverse effects of etoposide might originate from
the abnormal nuclear enlargement that is caused by severe DNA dam-
age and G2/M arrest. Therefore, we hypothesized that daurinol would
have fewer adverse effects because it does not induce significant nuclear
enlargement, as it can induce S-phase arrest without causing severe
DNA damage.
Daurinol Exerts Antitumorigenic Effects
in Nude Mice Xenografts
To test our hypothesis about the severity of daurinol adverse effects
in vivo, we investigated the antitumor effects and adverse effects of
daurinol and etoposide treatment in mice. Two independent in vivo
experiments were performed using a nude mice xenograft model. The
Figure 4. Effect of daurinol on the expression and phosphorylation of cell cycle regulatory proteins. HCT116 cells were treated with 5 μM
daurinol for 2, 12, 24, and 48 hours. (A) Representative immunoblots are shown from three independent experiments. The relative expres-
sion of p-ATM (Ser1981)/ATM (B), p-Chk1 (Ser317)/Chk1 (C), p-Chk1 (Ser345)/Chk1 (D), p-Chk2 (Thr68)/Chk2 (E), p-Cdk2 (Tyr15)/Cdk2 (F),
p-Cdc2 (Tyr15)/Cdc2 (G), E2F-1/β-actin (H), Cyc E/β-actin (I), Cyc A/β-actin (J), Cdc25A/β-actin (K), Cdk4/β-actin (L), and Cyc D1/β-actin (M)
were determined by densitometry. Columns and error bars indicate mean± SEM from three independent experiments. *P< .05, **P< .01,
and ***P < .001 for significant differences between the vehicle control and daurinol-treated cells at each time point.
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Figure 5. Effects of daurinol and etoposide on the nucleus size of HCT116 cells were evaluated by fluorescence microscopy (A–C) and
flow cytometry (D and E). HCT116 cells were treated with daurinol (2.5, 5, and 10 μM) or 10 μM etoposide for 48 hours. Cellular DNA was
labeled with propidium iodide for visualization and flow cytometric DNA content analysis. (A) Fluorescence microscopic images of
HCT116 cells treated with 5 μM daurinol or 10 μM etoposide for 48 hours. Pictures are representative of three independent experiments
(bar, 10 μm). Size of nucleus after treatment with daurinol or etoposide was determined using fluorescence microscopy and the circle mea-
surement algorithm of themicroscope software. (B) Distribution of nucleus size of HCT116 cells treated with 5 μMdaurinol or 10 μMetopo-
side for 48 hours. (C) Mean value of nucleus diameter. Columns and error bars indicate mean ± SD (n = 200). ***P < .001, for significant
differences from the vehicle control. (D) Flow cytometric analysis of HCT116 cells treated with 5 μMdaurinol or 10 μMetoposide. The FSC-H,
FL2-A, and FL2-Whistogramplots represent cell size, cell cycle, and nucleus size, respectively. Histograms are representative of quadruplicate
experiments. (E) Differences in the distributions of the FL2-W value (nucleus size) between vehicle control and chemical-treated cells were
quantitatively determined using Kolmogorov-Smirnov statistics. Index of similarity is theD/s(n) value of Kolmogorov-Smirnov statistics. Columns
and error bars indicate mean ± SD from quadruplicate experiments. ***P< .001, for significant differences from the etoposide treatment.
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first experiment was performed to evaluate the antitumor activity, toxic-
ity, and their persistence of daurinol and etoposide treatment. Daurinol
(1, 5, 10, and 20 mg/kg) or etoposide (20 mg/kg) were administered
three times weekly for 2 weeks, and mice were maintained for addi-
tional 2 weeks before sacrificing. Both daurinol (1-20 mg/kg) and
etoposide (20 mg/kg) displayed potent antitumor activities because
the tumor volumes of all treatment groups were significantly lower than
those of the vehicle-treated group (Figure 6, B andD). Tumor weights of
mice treated with daurinol (5 and 20 mg/kg) or etoposide were also sig-
nificantly decreased compared to the vehicle-treated group (Figure 6C).
Importantly, the body weights of mice treated with daurinol were similar
to those of vehicle-treated mice, whereas the weights of mice treated with
etoposide were significantly decreased (Figure 6A).
A second round of in vivo experiments was performed to confirm
antitumor activity and toxicity and to investigate changes in hematolog-
ical parameters and protein expression. In these experiments, mice were
treated with daurinol (5, 10, and 20 mg/kg) or etoposide (20 mg/kg)
twice weekly for 3 weeks. We again found significant antitumor activity
of daurinol and etoposide (Figure 7, B and C ), and the body weights of
mice treated with etoposide were slightly decreased compared to those
of daurinol-treated and vehicle-treated mice (Figure 7A). The inhibi-
tion of DNA synthesis by daurinol and etoposide was also determined
using BrdU immunohistochemical analysis. BrdU incorporation in mice
treated with daurinol (5, 20 mg/kg) or etoposide (20 mg/kg) was sig-
nificantly decreased compared to vehicle-treated mice (Figure 7D), and
this result is consistent with our in vitro studies. Western blot analysis
using total cell lysates prepared from xenograft tumors demonstrated
activation of the ATM/Chk/Cdc25A pathway, although only the phos-
phorylation of Chk1 at Ser345 was significantly different (Figure 7E).
No significant damage of normal organ tissues, including liver, kidney,
and colon, was observed in either the daurinol- or etoposide-treated
mice (Figure W8).
Daurinol Induces Less Hematological Damage than Etoposide
in Nude Mice Xenograft Models
We investigated hematological parameters in nude mice treated with
daurinol or etoposide to evaluate the hematological toxicities of the
tested chemicals. White blood cell counts (WBCs) of mice treated with
etoposide (20 mg/kg) were significantly lower than those of vehicle-
treated mice, whereas the WBCs of mice treated with daurinol (5, 10,
and 20 mg/kg) were comparable to vehicle-treated mice. Similarly, red
blood cell counts (RBCs) and hemoglobin contents of mice treated with
etoposide (20 mg/kg) were significantly lower than those of vehicle-
treated and daurinol-treated mice. Hematocrits (%) displayed similar
patterns to the results of WBCs, RBCs, and hemoglobin. Etoposide treat-
ment significantly decreased the hematocrit (%) compared with the
vehicle-treated group, whereas daurinol treatment did not, except at the
10-mg/kg dose. The number of platelets between vehicle-treated and
Figure 6. Antitumor activity of daurinol and etoposide in nude mice xenograft models of HCT116 cells. Daurinol (1, 5, 10, and 20 mg/kg)
or etoposide (20 mg/kg) were administered intraperitoneally three times weekly for 2 weeks. Body weights (A) and tumor volumes (B)
were monitored for 4 weeks after the initial injection of chemicals to evaluate toxicity, antitumor effects, and their persistence of daurinol
and etoposide treatment. (C) On day 29, tumors were removed and weighed. Data are expressed as mean ± SD (n = 10). *P < .05 and
**P < .01, for significant differences from the vehicle-treated group. (D) Photographs of tumors removed from mice treated with vehicle
control, daurinol (20 mg/kg), or etoposide (20 mg/kg).
Neoplasia Vol. 13, No. 11, 2011 Antitumor Effect of Daurinol with Low Side Effects Kang et al. 1053
daurinol-treated mice was comparable, except in the 5-mg/kg daurinol
treatment group. The platelet counts of mice treated with etoposide
(20 mg/kg) were slightly increased compared to the vehicle-treated
group (Table 1). Hematological damage was also observed by histologic
examination in the bone marrow of mice treated with etoposide
(Figure W8, A–C ).
Taken together, the results of the in vivo experiments lead us to
conclude that daurinol, a natural topoisomerase IIα inhibitor, has a
potent antitumor effect in mice, with lower adverse effects, such as loss
of body weight and hematological damage, compared to those induced
by etoposide.
Discussion
In the present study, we report that daurinol is a promising anticancer
agent that causes fewer adverse effects, such as myelosuppression, than
etoposide, a well-defined clinical anticancer agent [4,13]. To demon-
strate this, we investigated the similarities and differences of daurinol
and etoposide in depth. Both daurinol and etoposide significantly in-
hibited DNA synthesis and cell viability in HCT116 human colon
cancer cells. Etoposide, a human topoisomerase IIα poison, induced
severe DNA damage and cell cycle arrest at G2/M phase in HCT116
cells, whereas daurinol seems to be a catalytic inhibitor of topoisome-
rase IIα, which induced S-phase arrest without causing severe DNA
Figure 7. Evaluation of antitumor activities and molecular effects of daurinol and etoposide in nude mice xenograft models. Daurinol (5,
10, and 20 mg/kg) or etoposide (20 mg/kg) were administered intraperitoneally twice weekly for 3 weeks. Body weights (A) and tumor
volumes (B) were monitored for 3 weeks. On day 18, tumors were removed for immunohistochemistry and Western blot analysis.
(C) Tumor weights. (D) Inhibition of DNA synthesis in xenograft tumors was measured by BrdU incorporation immunostaining. Data
are expressed as mean ± SD (n = 10). *P < .05 and **P < .01, for significant differences from the vehicle-treated group. (E) Western
blot analysis of expression and phosphorylation of cell cycle regulatory proteins from tumors of nude mice treated with the vehicle
control or daurinol (20 mg/kg). Columns and error bars indicate mean ± SEM (n = 5). *P < .05 for significant differences from the
vehicle-treated group.
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damage. Etoposide induced significant nuclear enlargement of
HCT116 cells, whereas daurinol did not. We speculate that the nuclear
enlargement, an abnormal chromosomal condition, could promote
genomic instability of tumor tissues as well as normal tissues and
may therefore be correlated with the adverse effects of etoposide. Thus,
we hypothesized that daurinol might be used as a substitute anticancer
agent that is less toxic to healthy tissues owing to its less severe geno-
toxic effects compared to etoposide. We tested this hypothesis in vivo
with nude mice xenograft experiments. Daurinol displayed strong anti-
tumor activity without any significant adverse effects, such as decreased
body weight, blood cell counts, hemoglobin content, and hematocrit,
unlike etoposide, which had significant effects on all hematological
parameters. The differences between daurinol and etoposide are summa-
rized in Figure 8A. Our experimental approaches, such as considering
nuclear size changes in vitro and comparative analysis between novel
candidates and old drugs, provide a practical strategy for the develop-
ment of anticancer agents with decreased adverse effects.
We could not observed nuclear enlargement in the kidney and liver
cells as well as actively dividing colon epithelium and bone marrow
cells of nude mice treated with etoposide. This result is a typical ex-
ample of discordance between in vitro and in vivo experiments. We
assumed that cells with enlarged, abnormal nuclei are very dangerous
to animals and may be actively eliminated in normal tissue by pro-
grammed cell death, such as apoptosis and macrophage engulfment
[9]. One possible explanation is that the effective concentration of
etoposide in normal tissue may be quite low compared with in vitro
cultured cells, and therefore, it was not sufficient to induce G2/M arrest
in the animal model because of the absorption, distribution, metabolism,
and/or excretion of the compound.
We also elucidated the molecular mechanism of S-phase arrest in-
duced by daurinol treatment. Daurinol-induced S-phase arrest can be
predicted by the inhibition of DNA synthesis. We found that S-phase
was the rate-limiting step of the cell cycle in HCT116 cells treated with
daurinol, that is, a greater number of daurinol-treated HCT116 cells
were in S-phase compared to vehicle control cells. The changes in
cellular signaling shown by Western blot analysis could also explain
the daurinol-induced S-phase arrest in HCT116 cells. Cdk2/cyclin E
and Cdk2/cyclin A complexes are involved in the initiation and progres-
sion of S-phase, respectively [33–35]. The up-regulation of cyclin E
at early times (12 and 24 hours) and continued high expression of
cyclin A at 12, 24, and 48 hours were observed after treatment with
daurinol, indicating enhanced S-phase initiation. In addition, the ex-
pression of E2F-1 was significantly increased at 24 hours of treatment.
E2F-1 is an important transcription factor regulating cell cycle control
and is known to transcribe cyclin E and cyclin A [39,40]. We also ex-
amined activation of the ATM/Chk/Cdc25A pathway, which recog-
nizes DNA damage in cells. Daurinol induced the phosphorylation of
ATM at Ser 1981, Chk1 at Ser317 and Ser345, and Chk2 at Thr 68
Table 1. Effect of Daurinol and Etoposide on the Hematological Parameters in Nude Mice Bearing HCT116 Cell Xenograft Tumors.
Control, 0 mg/kg Daurinol Etoposide, 20 mg/kg
5 mg/kg 10 mg/kg 20 mg/kg
WBCs (×103 cells/μl) 4.07 ± 2.42 2.60 ± 1.12 1.86 ± 0.74 1.63 ± 0.91 0.92 ± 0.43*
RBCs (×103 cells/μl) 9.66 ± 0.41 9.55 ± 0.37 8.82 ± 1.20 9.24 ± 1.03 7.74 ± 0.49*
Hemoglobin (g/dl) 15.59 ± 0.61 15.33 ± 0.68 14.27 ± 1.98 14.78 ± 1.60 12.31 ± 0.76*
Hematocrit (%) 48.61 ± 2.48 47.29 ± 2.09 43.48 ± 6.38† 45.44 ± 5.34 37.36 ± 2.92*
Platelets (×103 cells/μl) 1418 ± 145 916 ± 457† 1220 ± 462 1091 ± 470 1733 ± 263
*P < .001, for significant differences from the vehicle-treated group.
†P < .05, for significant differences from the vehicle-treated group.
Figure 8. (A) Comparison of daurinol and etoposide. (B) Schematic representation of the possible molecular mechanism of S-phase
arrest induced by daurinol treatment in human colon cancer cells.
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at later time points (24–48 hours). Daurinol also induced the degrada-
tion of Cdc25A at 24 to 48 hours of treatment. Cdc25A is degraded on
phosphorylation by the upstream signaling kinases Chk1 and Chk2
[33,36,37]. Cdc25A is a phosphatase that inhibits Cdk2 and Cdc2 ac-
tivities by dephosphorylation at Tyr15 residue, and Cdk2 and Cdc2 are
important cyclin-dependent kinases for the G1/S and G2/M transitions,
respectively [36,38]. Daurinol also increased the phosphorylation at
the Tyr 15 of Cdk2 and Cdc2 at 48 hours after treatment. These data
imply that daurinol can inhibit both G1/S and G2/M transitions at
48 hours. Taken together, these data suggest that daurinol-induced
S-phase arrest results from enhanced initiation and progression of S-phase
at early times (24 hours) and the concomitant inhibition of G1/S and
G2/M transition at later times (48 hours). A proposed model for the
signaling pathway of daurinol-induced S-phase arrest is shown in
Figure 8B.
We did not elucidate the signaling upstream of the regulation of
E2F-1, cyclin E, and cyclin A in detail, but these are crucial compo-
nents for understanding S-phase arrest induced by daurinol. Thus, fur-
ther investigation of these pathways is needed. ATM/ATR and Chk1/2
are possible candidates because it has recently been suggested that accu-
mulation of E2F-1 via phosphorylation by ATM/ATR and Chk1/2
may control cell cycle arrest, apoptosis, and DNA repair on DNA dam-
age in cells [41].
In the present study, we also found that expression of the Cdk4 and
cyclin D1 proteins, which are important cell cycle regulatory proteins
during G1 phase [35,42], decreased after daurinol treatment both
in vitro and in vivo (Figures 4, A, L, and M , and 7E ). These data also
indicate that daurinol treatment inhibits the G1 checkpoint. We pos-
tulate that moderate inhibition of each cell cycle checkpoint may con-
tribute to the overall slowing of the cell cycle in cancer cells. We also
hypothesize that the decrease of cyclin D1 may result from the inhi-
bition of the Wnt signaling, which is an important signaling pathway
in colon cancer initiation [43,44], because daurinol treatment com-
pletely inhibited mRNA expression of genes involved in the Wnt sig-
naling pathway in HCT116 cells according to complementary DNA
microarray experiments (data not shown). Therefore, we will further
study the inhibitory effect of daurinol on the Wnt signaling to eluci-
date the cancer chemopreventive effects of daurinol.
We demonstrated that daurinol inhibits human topoisomerase IIα
without the formation of the DNA cleavable complex. Thus, daurinol
could be a catalytic inhibitor that interferes with at least one step of the
catalytic cycle of topoisomerase. Further in-depth biochemical studies
are required to identify the exact step of the enzyme cycle that is inhib-
ited (e.g., DNA binding, ATP association/dissociation, magnesium ion
binding, or dissociation from DNA) [12]. Furthermore, the inhibition
of other topoisomerases, including topoisomerase I and IIβ, must also
be tested to fully characterize the biochemical mechanism underlying
daurinol-mediated inhibition of DNA synthesis.
The main structural difference between daurinol and etoposide is that
daurinol has an arylnaphthalene moiety, whereas etoposide contains an
aryltetraline moiety. The aryltertaline lignan teniposide (VM-26) and
etoposide are synthetic derivatives of podophyllotoxin, a natural plant
aryltetraline lignan [3]. Like etoposide, teniposide has been used to treat
various human cancers, including small cell lung cancer, testicular
cancer, and lymphoma [45]. Teniposide also induces G2/M arrest and
DNA damage in cancer cells [45,46] and has been reported to cause
severe hematological damage, such as myelosuppression, leukopenia,
and thrombopenia, in clinical cancer trails [47,48]. We propose that
daurinol is a promising lead compound for the development of a novel
anticancer agent that is similar to etoposide but has reduced adverse
effects, including myelosuppression. Therefore, strategies are needed
to synthesize or derive daurinol and to optimize its antitumor efficacy,
toxicity, solubility, and pharmacokinetics.
In summary, we have shown that daurinol, a novel plant arylnaphthalene
lignan, is a potential anticancer agent that causes less hematological
damage than the related clinical agent etoposide. However, further
studies of the molecular mechanisms of the anticancer effects of dau-
rinol, including upstream signaling and its mode of inhibition against
human topoisomerases, as well as preclinical and clinical trials of
daurinol, are needed.
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Figure W1. Daurinol inhibits both cell viability (mitochondrial dehydrogenase activity) and DNA synthesis (BrdU incorporation) in human
colon cancer DLD-1 cells. Cell survival after treatment with daurinol or etoposide for 24 and 48 hours was determined by CCK-8 assay
and BrdU incorporation ELISA in DLD-1 cells. Data are expressed as mean ± SD from triplicate experiments. *P < .05, **P < .01, and
***P < .001, for significant differences from the vehicle control.
Figure W2. Daurinol induces S-phase arrest in DLD-1 cells. The cell cycle was evaluated by flow cytometric DNA content analysis. DLD-1
cells were treated with 0 to 10 μM daurinol for 48 hours. The percentage of cells in S-phase is indicated on each graph. The graph is
representative of at least three independent experiments.
Figure W3. Daurinol inhibits human topoisomerase IIα activity. Inhibitory activity of daurinol and etoposide on human topoisomerase IIα
was evaluated by in vitro biochemical assay using a TopoGEN kit. The supercoiled DNA (pHOT1) substrate was reacted with human
topoisomerase IIα in the presence of daurinol (1 and 2 mM) or etoposide (0.5 and 2 mM). DNA relaxation was evaluated by agarose gel
electrophoresis in the absence of ethidium bromide.
Figure W4. Absorption spectrumof 10 μMdaurinol dissolved inDPBS.
Figure W5. Daurinol interacts with DNA. The interaction of daurinol and calf thymus DNA was evaluated through fluorescence spec-
troscopy. (A) Theoretical chemical equation of daurinol fluorescence quenching by interaction with DNA. (B) Fluorescence emission
spectrum of daurinol (λex = 260 nm). Daurinol (50, 40, 30, 20, 10, 5, or 0 μM) was dissolved in DPBS with 2% DMSO (1–7, respectively).
The graph is representative of three independent experiments. (C) Fluorescence emission spectra of 30 μMdaurinol in DPBSwith increasing
concentration of calf thymus DNA (from 1 to 7: 0.19, 0.38, 0.95, 1.90, 2.85, or 3.80 mM) (λex = 260 nm). DNA (3.8 mM) without daurinol did
not emit fluorescence (dotted line). The graph is representative of four independent experiments. (D) Stern-Volmer plot of daurinol fluores-
cence quenching with increasing concentrations of calf thymus DNA. The excitation wavelength was 260 nm, and the monitoring wave-
length was 480 nm at room temperature. The graph is representative of four independent experiments.
Figure W6. Differential interference contrast microscope images of HCT116 cells treated with 5 μM daurinol or 10 μM etoposide for
48 hours (bar, 20 μm).
Figure W7. The effects of daurinol and etoposide on the nuclear size of HCT116 cells were evaluated by fluorescence microscopy (A–C)
and flow cytometry (D and E). HCT116 cells were treated with daurinol (2.5, 5, and 10 μM) or 10 μM etoposide for 24 hours. Cellular DNA
was stained with propidium iodide for visualization and flow cytometric DNA content analysis. (A) Fluorescence microscopic images of
HCT116 cells treated with 5 μM daurinol or 10 μM etoposide for 24 hours. Pictures are representative of three independent experiments
(bar, 10 μm). Nucleus size after treatment with daurinol or etoposide was determined by fluorescence microscopy and the circle mea-
surement algorithm of the microscope software. (B) Distribution of nuclear size in HCT116 cells treated with 5 μM daurinol or 10 μM
etoposide. (C) Mean diameter of nuclei. Columns and error bars indicate mean ± SD (n = 200). ***P < .001, for significant differences
from the vehicle control. (D) Flow cytometric analysis of HCT116 cells treated with 5 μM daurinol or 10 μM etoposide for 24 hours. FSC-H,
FL2-A, and FL2-W histogram plots represent cell size, cell cycle, and nucleus size, respectively. Histograms are representative of quadru-
plicate experiments. (E) Differences in the distribution of the FL2-W values (nucleus size) between vehicle control and chemical-treated
cells were quantitatively determined using Kolmogorov-Smirnov statistics. The index of similarity is the D/s(n) value of the Kolmogorov-
Smirnov statistics. Columns and error bars indicate mean ± SD from quadruplicate experiments. ***P < .001, for significant differ-
ences from the etoposide treatment.
Figure W8. Effect of daurinol and etoposide on normal tissues of nude mice. Organs were removed from mice of each group after
intraperitoneal injection of vehicle control, 20 mg/kg daurinol, or 20 mg/kg etoposide twice weekly for 3 weeks. Paraffin-embedded
sections were stained with hematoxylin and eosin (n= 10). (A) Bone marrow of vehicle-treated mice. (B) Bone marrow of daurinol-treated
mice. (C) Bone marrow of etoposide-treated mice. (D) Liver of vehicle-treated mice. (E) Liver of daurinol-treated mice. (F) Liver of etoposide-
treatedmice. (G) Kidney of vehicle-treatedmice. (H) Kidney of daurinol-treatedmice. (I) Kidney of etoposide-treatedmice. (J) Colon of vehicle-
treated mice. (K) Colon of daurinol-treated mice. (L) Colon of etoposide-treated mice (bar, 20 μm).
